1. Generics Bulletin
  3. >>Deals

UK’s BGMA Condemns Anti-Competitive Behavior

 
• By Akriti Seth

The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.

Anti_Competitive_Practices
BGMA reacts to CMA’s investigation into alleged anti-competitive agreements • Source: Shutterstock

After Aspen Pharmacare Holdings Ltd admitted that it was a party to an illegal, anti-competitive agreement and paid the UK National Health Service (NHS) £8m following an investigation by the Competition and Markets Authority (CMA), the British Generic Manufacturers Association (BGMA) has reacted to the CMA’s investigation by condemning anti-competitive behavior.

Aspen’s settlement resulted from an investigation by the CMA into anti-competitive arrangements involving the supply of fludrocortisone 0.1mg tablets. (Also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By Dave Wallace

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

 
• By Urtė Fultinavičiūtė

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.